QRG Capital Management Inc. Has $4.44 Million Position in Sanofi $SNY

QRG Capital Management Inc. cut its position in Sanofi (NASDAQ:SNY) by 36.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 93,954 shares of the company’s stock after selling 52,873 shares during the quarter. QRG Capital Management Inc.’s holdings in Sanofi were worth $4,435,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Financial Consulate Inc. bought a new position in shares of Sanofi in the 3rd quarter worth about $26,000. Ameritas Advisory Services LLC bought a new stake in shares of Sanofi in the 2nd quarter worth $28,000. First Horizon Corp purchased a new stake in shares of Sanofi in the third quarter valued at about $33,000. Salomon & Ludwin LLC lifted its position in shares of Sanofi by 1,046.3% during the 3rd quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock worth $39,000 after buying an additional 701 shares in the last quarter. Finally, Concord Wealth Partners increased its position in shares of Sanofi by 510.3% during the second quarter. Concord Wealth Partners now owns 885 shares of the company’s stock valued at $43,000 after acquiring an additional 740 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Sanofi Stock Down 1.9%

Shares of NASDAQ:SNY opened at $46.59 on Monday. The firm has a fifty day moving average price of $49.00 and a two-hundred day moving average price of $48.84. The company has a market cap of $113.63 billion, a price-to-earnings ratio of 10.91, a PEG ratio of 1.16 and a beta of 0.45. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.30. Sanofi has a one year low of $44.62 and a one year high of $60.12.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 24th. The company reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $1.31. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The company had revenue of $15.46 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter last year, the business posted $2.25 earnings per share. The firm’s revenue was down 7.5% compared to the same quarter last year. Analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Cowen reiterated a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a report on Friday. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Finally, HSBC reissued a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, Sanofi has a consensus rating of “Moderate Buy” and a consensus target price of $62.67.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.